New York State Teachers Retirement System Has $723,000 Stake in USANA Health Sciences, Inc. (NYSE:USNA)

New York State Teachers Retirement System trimmed its position in USANA Health Sciences, Inc. (NYSE:USNA) by 2.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 13,486 shares of the company’s stock after selling 300 shares during the quarter. New York State Teachers Retirement System’s holdings in USANA Health Sciences were worth $723,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Teachers Retirement System of The State of Kentucky raised its stake in USANA Health Sciences by 5.1% during the second quarter. Teachers Retirement System of The State of Kentucky now owns 3,996 shares of the company’s stock worth $252,000 after acquiring an additional 195 shares in the last quarter. Thrivent Financial for Lutherans raised its stake in USANA Health Sciences by 1.8% during the third quarter. Thrivent Financial for Lutherans now owns 11,510 shares of the company’s stock worth $645,000 after acquiring an additional 199 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in USANA Health Sciences by 4.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,307 shares of the company’s stock worth $282,000 after acquiring an additional 205 shares in the last quarter. Franklin Resources Inc. raised its stake in USANA Health Sciences by 4.1% during the first quarter. Franklin Resources Inc. now owns 5,994 shares of the company’s stock worth $377,000 after acquiring an additional 234 shares in the last quarter. Finally, Nuveen Asset Management LLC raised its stake in USANA Health Sciences by 0.8% during the second quarter. Nuveen Asset Management LLC now owns 33,336 shares of the company’s stock worth $2,102,000 after acquiring an additional 273 shares in the last quarter. 54.25% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms have issued reports on USNA. StockNews.com upgraded USANA Health Sciences from a “buy” rating to a “strong-buy” rating in a research note on Friday, January 12th. DA Davidson decreased their target price on USANA Health Sciences from $53.00 to $48.00 and set a “neutral” rating on the stock in a report on Thursday, February 22nd.

Insider Transactions at USANA Health Sciences

In related news, insider David Mulham Mulham sold 4,311 shares of USANA Health Sciences stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $47.76, for a total value of $205,893.36. Following the completion of the sale, the insider now directly owns 7,825 shares in the company, valued at $373,722. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, insider David Mulham Mulham sold 4,311 shares of USANA Health Sciences stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $47.76, for a total value of $205,893.36. Following the completion of the sale, the insider now directly owns 7,825 shares in the company, valued at $373,722. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Robert A. Sinnott sold 3,945 shares of USANA Health Sciences stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $46.55, for a total value of $183,639.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,807 shares of company stock worth $1,200,791. Insiders own 0.33% of the company’s stock.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $43.47 on Friday. The stock’s fifty day moving average is $47.80 and its 200-day moving average is $49.37. The stock has a market capitalization of $836.36 million, a PE ratio of 13.17, a PEG ratio of 1.32 and a beta of 0.91. USANA Health Sciences, Inc. has a 52 week low of $42.59 and a 52 week high of $69.60.

USANA Health Sciences (NYSE:USNA) last announced its earnings results on Tuesday, February 6th. The company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.52 by $0.35. The company had revenue of $221.08 million for the quarter, compared to analysts’ expectations of $206.70 million. USANA Health Sciences had a return on equity of 13.49% and a net margin of 6.93%. As a group, analysts forecast that USANA Health Sciences, Inc. will post 2.73 earnings per share for the current fiscal year.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.